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Introduction
Iron is a paradoxical element, essential for living organ-
isms but also potentially toxic. Indeed, iron has the ability 
to readily accept and donate electrons, interconverting 
from soluble ferrous form (Fe2+) to the insoluble ferric 
form (Fe3+). Th   is capacity allows iron to play a major role 
in oxygen transport (as the central part of hemoglobin) 
but also in electron transfer, nitrogen ﬁ  xation or DNA 
synthesis, all essential reactions for living organisms. 
Indeed, iron deﬁ  ciency is the main cause of anemia [1] as 
well as a cause of fatigue [2,3] and decreased eﬀ  ort 
capacity [4,5]. However, despite a high frequency of 
anemia among critically ill patients, with 60 to 66% being 
anemic at intensive care unit (ICU) admission [6,7], to 
date little is known about iron deﬁ   ciency and iron 
metabolism in critically ill patients [8]. Th  e interaction 
between inﬂ   ammation and iron metabolism interferes 
with the usual iron metabolism variables and renders this 
metabolism diﬃ   cult to investigate [9,10].
Th   e recent discovery of hepcidin (the master regulator of 
iron metabolism) has shed new light on the regulation of 
iron homeostasis and has helped our understanding of 
complex clinical situations, such as those observed in 
critically ill patients, where several regulatory circuits 
inter  fere with iron metabolism [11]. Th  e purpose of this 
article is to review iron metabolism and anemia in critically 
ill patients as well as the role of hepcidin, and to discuss 
the indications for iron supplementation in these patients.
Iron metabolism overview and the role of hepcidin
Although iron is essential for life, it may also be toxic 
because of its capacity to react with oxygen and to 
promote the production of free radicals. Th  is duality is 
found in human pathology: Iron deﬁ  ciency (because of 
poor iron intake, abnormal blood losses etc...) presents 
with anemia and fatigue; whereas iron overload (mainly 
in hereditary hemochromatosis and following repeated 
blood transfusions) induces multiple organ dysfunctions 
(including liver ﬁ   brosis, cirrhosis, cardiomyopathy, 
diabetes...). Th   is explains why iron homeostasis must be 
ﬁ  nely tuned to avoid both deﬁ  ciency and excess.
Iron turnover in the organism occurs almost in a closed 
circuit (Fig.  1). Indeed, global iron turnover through 
losses (because of bleeding or cell desquamation) and 
dietary uptake (by duodenal cells) is only 1 to 2 mg per 
day, compared to approximately 3 to 4 g of iron contained 
in the organism. In fact, most of the iron available for 
erythropoiesis comes from the catabolism of senescent 
red blood cells (RBCs) by macrophages in the reticulo-
endothelial system (called eythrophagocytosis). As shown 
in Figure  1, more than two-thirds of the body’s iron 
content is incorporated into hemoglobin, either in bone 
marrow erythroid progenitors or in circulating RBCs. 
Once aged, these RBCs are internalized and hemo  globin 
is degraded in tissue macrophages. Iron is then 
transferred to the macrophage cytosol and either released 
into the blood ﬂ  ow or stored in ferritin molecules. In the 
plasma, transferrin binds newly released iron to allow its 
mobilization from storage sites (mainly the spleen and to 
a lesser extent the liver) to utilization sites (mainly the 
bone marrow). Erythropoiesis requires about 25 to 30 mg 
of iron daily. It has to be stressed that the amount of iron 
present in the plasma at any time is small (about 3 mg) 
compared to the daily amount of iron needed for 
erythropoiesis. Iron metabolism is therefore ﬁ  nely tuned, 
with hepcidin being central to its regulation [12].
Hepcidin is a small 25 amino acid peptide mainly 
produced by the liver. It is produced as an 84 amino acid 
pre-pro-peptide. Pro-hepcidin has been shown to be 
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under the German Copyright Law.biologically inactive. Hepcidin acts by binding to ferro-
portin, which is the sole known iron exporter [13]. Th  e 
binding of hepcidin to ferroportin induces its internali-
zation and degradation in the cytosol, which prevents the 
release of intracellular iron [13]. Ferroportin is mainly 
expressed in macrophages and duodenal cells, allowing, 
respectively, iron recycling (after eythrophagocytosis) 
and iron absorption from the digestive lumen (after 
internali  zation of iron through natural resistance-asso-
ciated macrophage protein [nRAMP]/duodenal metal 
transporter [DMT1]). Induction of hepcidin synthesis 
may thus lead to iron-restricted erythropoiesis (by 
inhibit  ing the release of iron from macrophages to the 
bone marrow) and to dietary iron deﬁ  ciency (by inhibit-
ing the uptake of iron from the digestive duodenal cells). 
Hepcidin acts as a `hyposideremic’ hormone, aimed at 
inhibiting iron absorption and reducing the level of iron 
in the blood.
Because hepcidin plays this central role in iron 
metabolism regulation, its synthesis is ﬁ  nely regulated 
(Fig.  2) [11,12]. Hepcidin synthesis is induced by iron 
overload and inﬂ   ammation, whereas iron deﬁ  ciency, 
hypoxia and erythroid expansion repress its synthesis. 
Th   e molecular mechanisms implicated in these complex 
regulations are not fully understood (see [12] for review), 
but the induction of hepcidin synthesis by inﬂ  ammation 
has been shown to be interleukin (IL)-6 dependent [14]. 
Th  is interaction between hepcidin and inﬂ  ammation 
makes hepcidin the principal agent responsible for the 
iron-restricted erythropoiesis observed during chronic 
diseases, ultimately leading to the `anemia of chronic 
disease’ (or anemia of inﬂ   ammation) [15,16]. On the 
other hand, hepcidin synthesis is repressed by both iron 
deﬁ   ciency and stimulation of erythropoiesis [11,12]. 
Although the precise mechanisms involved in the repres-
sion of hepcidin are not fully understood, it appears that 
matriptase 2, a membrane-bound serine protease expressed 
in hepatocytes, seems to play a key role in repressing 
hepcidin synthesis in iron deﬁ   ciency conditions [17]. 
Repression of hepcidin by erythropoiesis stimulation is 
even less well understood, but seems to involve bone 
marrow erythropoietic activity rather than erythropoietin 
itself [18,19]. Hypoxia-inducible factor (HIF) or CCAAT 
enhancer binding protein-alpha pathways have also been 
proposed [12]. In human pathology, little is known. 
Growth diﬀ  erentiation factor 15, a member of the trans-
forming growth factor (TGF)-β family produced by late 
erythroblasts, has been found in high levels in patients 
with beta-thalassemia syndromes and has been shown to 
repress hepcidin synthesis [20]. Th  ese two opposite 
stimuli are found in the anemia of critically ill patients, as 
discussed below.
Figure 1. Distribution of iron in the body. Erythrocytes contain almost two thirds of all body iron. Any blood loss may thus lead to direct iron 
loss. Serum iron, representing less than 1/103 of the total iron content, is very limited at any time compared to the daily amount of iron needed for 
erythropoiesis. Hepatocytes and tissue macrophages are the main sites of iron storage. Iron is absorbed by intestinal cells through the duodenal 
metal transporter (DMT-1 apical transporter) and exported into the blood circulation via ferroportin.
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the critically Ill: hepcidin as a diagnostic tool?
Anemia is not only very frequent among critically ill 
patients, it is also associated with increased transfusion 
rates and worse outcomes (increased length of stay, 
increased mortality) [6,7]. However, recent recommen-
dations have led to a decrease in transfusion triggers [21]. 
Nowadays, anemia is present at ICU discharge in at least 
75% of all patients when considering their last measured 
hemoglobin levels [22]. Furthermore, anemia may also be 
prolonged after discharge, with a median time to 
recovery of 11 weeks and more than half of the patients 
still anemic 6 months after ICU discharge [23]. Th  ere  is, 
therefore, need for a better understanding of the mecha-
nisms of anemia in the critically ill and an evaluation of 
therapeutic options.
Th  e two main contributing factors for anemia in the 
critically ill are inﬂ  ammation and iron deﬁ  ciency, which 
have opposite eﬀ  ects on iron metabolism (see above). 
Until recently, inﬂ  ammation, rather than iron deﬁ  ciency, 
was considered to play the major role. Indeed, the iron 
proﬁ  le of critically ill patients constantly shows hallmarks 
of anemia of inﬂ  ammation. However, this topic has not 
been considered a matter of great interest in the past, 
with few studies undertaken [9]. Inﬂ  ammation is frequent 
in critical illness, whatever the underlying pathology. Th  e 
anemia of critically ill patients is indeed similar to the 
anemia of inﬂ   ammation, with blunted erythropoietic 
response and activation of RBC destruction by macro-
phages [15,24]. Low serum iron and high ferritin levels 
constitute the typical iron proﬁ  le of critically ill patients 
and are indicative of an inﬂ  ammatory iron proﬁ  le [25,26]. 
Figure 2. Regulation of iron metabolism in anemia of the critically ill patient. Two opposite stimuli regulate hepcidin, which is the master 
regulator of iron metabolism. Hepcidin binds to ferroportin, inducing its internalization and destruction, thus avoiding iron export. Infl  ammation 
induces hepcidin synthesis, while iron defi  ciency, blood spoliation and erythropoiesis stimulation repress it. A low hepcidin level is required to allow 
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(through IL-1) independently of the level of iron stores, 
elevated ferritin levels are no longer indicative of iron 
stores in the context of inﬂ  ammation [10]. Th  us,  despite 
an iron proﬁ   le that mimics iron overload (with high 
ferritin levels), iron deﬁ  ciency may exist in these critically 
ill patients.
Indeed, daily blood losses are far from negligible, either 
through repeated blood sampling [6,27], surgical site 
bleeding, other invasive procedures (drainage, catheter 
placement, renal replacement therapy...) or occult bleed-
ing [26]. Th  e median blood loss for anemic critically ill 
patients has been estimated to be as high as 128 ml per 
day [26]. Th   is may represent a median iron loss as high as 
64 mg per day. As daily iron intake is less than 20 fold 
iron losses, iron deﬁ   ciency could easily appear in 
critically ill patients.
Iron deﬁ  ciency may thus coexist with inﬂ  ammation. In 
addition, iron deﬁ  ciency is not infrequent in the general 
population [28], and also in the elderly [3,29] or patients 
suﬀ  ering from heart failure [30]. Th  e frequency of iron 
deﬁ  ciency on ICU admission may thus be around 35% 
[31,32]. However, the diagnosis of iron deﬁ  ciency  is 
diﬃ   cult in the context of inﬂ  ammation because the usual 
indicators of iron deﬁ  ciency are no longer valid [9,10]. 
Because inﬂ  ammation induces ferritin synthesis, serum 
ferritin levels are no longer indicative of iron stores. New 
biological markers are thus required for the diagnosis of 
iron deﬁ  ciency in the context of inﬂ  ammation (Figure 3) 
[10]. Below are the main biological markers that can be 
used:
•  Percentage of hypochromic RBCs. Th  ese  hypo-
chromic RBCs result from iron-restricted erythro-
poiesis. Schematically, a value of > 10% hypochromic 
erythrocytes (normal <  2.5%) is indicative of iron-
restricted erythropoiesis over the past 3 months (this 
being the RBC lifespan).
•  Reticulocyte hemoglobin content. Reticulocyte hemo-
globin content below 28 pg is also indicative of iron-
restricted erythropoiesis over the past 2 to 3 days 
(this being the lifespan of reticulocytes). Recently, a 
low reticulocyte hemoglobin content on admission 
was shown to be associated with higher transfusion 
rates in critically ill patients [32].
• Erythrocyte zinc protoporphyrin (ZPP). During 
erythro  poiesis, Fe is normally incorporated into 
protoporphyrin IX to form heme. In iron deﬁ  ciency, 
zinc is substituted for iron, leading to the formation 
of ZPP. Increased erythrocyte ZPP is thus indicative 
of iron deﬁ  ciency.
•  Soluble transferrin receptor (sTfR). Transferrin recep-
tors allow the internalization of iron into erythroid 
progenitor. Th  eir synthesis is increased as bone 
marrow erythropoietic activity increases. When iron 
supply is insuﬃ   cient, a truncated form of transferrin 
receptor appears in the serum. sTfR is thus indicative 
of iron-deﬁ   ciency anemia. Th  is marker is widely 
proposed, however there is no gold standard for its 
measurement.
•  sTfR/log ferritin ratio (called the ferritin index). Th  is 
is proposed as a marker to diﬀ  erentiate  between 
anemia of inﬂ  ammation and the combined situation 
of iron deﬁ  ciency and anemia of inﬂ  ammation, taking 
into account the “uncovered need for iron” on the one 
hand and the “iron stores” on the other [15].
Complex algorithms combining all these variables have 
been proposed for the diagnosis of iron deﬁ  ciency in the 
presence of inﬂ   ammation [10,15]; however, none are 
clinically validated and the cut-oﬀ   values for each variable 
are unknown. Moreover, all but sTfR cannot be used after 
recent blood transfusion.
Being central to iron metabolism, hepcidin may be a 
marker of iron deﬁ  ciency, even in the presence of inﬂ  am-
mation. Indeed, using animal models, we and others have 
demonstrated that hepcidin can be repressed despite 
inﬂ  ammation [33–35] and that this repression is associa-
ted with spleen iron mobilization [34]. Th  ese observa-
tions reinforce the concept that iron deﬁ  ciency  may 
coexist with anemia of inﬂ  ammation [15]. Measurement 
of hepcidin concentrations may thus be helpful for the 
diagnosis of iron deﬁ  ciency in the context of inﬂ  am  ma-
tion. Additionally, many hepcidin assays have been 
recently developed [36]. Most studies evaluating the use 
of hepcidin concentrations to diagnose iron deﬁ  ciency 
during inﬂ  ammation have used ELISA-based values show-
ing virtually undetectable levels [35] or normal values 
[37,38] of hepcidin despite inﬂ  ammation  (supposed  to 
increase hepcidin synthesis). Measurement of hepcidin 
concentrations could be accurate in the diagnosis of iron 
deﬁ  ciency in critically ill anemic patients using a cut-oﬀ   
value of less than 130 ng/l [38].
Is there a place for iron supplementation or 
treatment in critically ill patients?
Because iron deﬁ  ciency may coexist with inﬂ  ammation 
in critically ill patients [9,10,32,38] and because iron may 
be mobilized from spleen stores in the presence of 
inﬂ   ammation [34,35], one could propose that iron be 
given to critically ill patients.
Because blood transfusion is not an option to fully 
correct the anemia in critically ill patients [6,21], the use 
of alternatives such as erythropoiesis-stimulating agents 
or iron has been suggested. Erythropoiesis-stimulating 
agents have already been studied in the critically ill. Th  ey 
have not been shown to be useful [39] and are beyond the 
scope of this review. In addition, iron deﬁ  ciency  may 
concern up to 40% of critically ill patients [10,31,32,38]. 
Iron may thus be needed not only for erythropoiesis but 
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deﬁ   ciency, having been shown to improve functional 
capacity in women [40] and in cardiac patients [41]. 
However, iron is also a toxic compound with the ability to 
induce oxidative stress or to promote bacterial growth 
and may thus not be suitable in the ICU context. Indeed, 
free iron may induce oxidative stress through the Fenton 
reaction. Large amounts of iron, exceeding the transferrin 
iron-binding capacity, may thus be toxic by inducing the 
release of free iron and causing oxidative stress. Th  is 
probably explains the increased mortality associated with 
large amounts of iron administration (around the DL50) 
observed in an animal model of peritonitis [42]. However, 
no increase in oxidative stress has been demonstrated in 
human practice [43]. Th  ere is also a link between iron 
and infection, with iron being needed for bacterial 
growth. Th  e decrease in serum iron concentration may 
be a defense mechanism against bacterial proliferation. 
However, bacteria have developed mechanisms for iron 
acquisition including the release of siderophores. Th  e 
respective aﬃ     nity for iron between transferrin and 
sidero  phores is probably what matters [44]. In clinical 
studies, this link between iron and infection has 
essentially been supported by experimental data on 
micro  organisms and retrospective studies in hemo  dialy-
sis patients showing an association between hyper  fer-
ritinemia and the likelihood of infection. However, avail-
able observational studies in postoperative or critically ill 
patients show no association between intravenous iron 
administration and risk of infection [45]. Furthermore, 
iron deﬁ  ciency is associated with impaired immunity [46] 
and may, therefore, be responsible for increased suscep-
tibility to infection [32] as well as being associated with 
increased length of stay in the ICU [31].
Iron may thus be suggested to correct iron deﬁ  ciency, 
even in the presence of inﬂ  ammation, similar to its pro-
posed use in the treatment of patients with cancer-induced 
anemia [15,47]. Iron may be given using either intravenous 
or enteral routes. For the latter, ferrous iron is used. Iron 
absorption requires a mildly acidic medium (i.e., without 
concomitant use of proton pump inhibitors) and ascorbic 
acid. However, absorption may be reduced by inﬂ  am  ma-
tion because of the decrease in ferroportin levels induced 
by hepcidin, or because of frequent gastro  intestinal 
adverse eﬀ  ects.  Th  e intravenous route allows adminis-
tration of much higher doses with few adverse eﬀ  ects (with 
the notable exception of anaphy  lactic shock following iron 
dextran injections) and no diﬃ     culty of absorption. A 
recent meta-analysis showed that non-dextran iron was 
superior to enteral iron for the correction of anemia, with 
few adverse eﬀ  ects [48]. However, the only available study 
of intravenous iron showed no beneﬁ  cial eﬀ  ect on erythro-
poiesis when used without erythropoiesis-stimulating 
agents [25]. Th   e only study of iron deﬁ  ciency treatment in 
critically ill patients is the study by Pieracci et al., which 
showed a reduced transfusion rate in patients with baseline 
iron deﬁ  ciency treated with enteral iron supplementation 
(ferrous sulfate 325 mg three times daily) [49]. In this 
study, oral iron supplementation was not associated with 
an increased risk of infection.
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deﬁ  ciency and/or to enhance the response to erythro-
poiesis-stimulating agents in critically ill patients, but 
further studies are needed to rule out the potential risks 
of iron treatment (i.e., oxidative stress induction, 
increased risk of infection) and to deﬁ  ne the best route of 
administration. In Figure 4, we propose an algorithm for 
iron deﬁ  ciency diagnosis and treatment. We believe that 
iron should be given to critically ill patients only in cases 
of iron deﬁ   ciency, at best deﬁ   ned according to a low 
hepcidin level. Th   e dose of iron needed may be assessed 
using the following formula:
iron deﬁ  cit = 
body weight (kg) × (target Hb – actual Hb) × 2.4.
Because elevated iron concentrations induce the 
synthesis of hepcidin, which in turn may reduce iron 
availability, the total dose of iron should be given using 
fractionated injections. Further clinical studies are 
needed to validate these propositions.
Conclusion
Th  e discovery of hepcidin sheds new light on our 
knowledge of iron metabolism and may enable easier 
recognition of iron deﬁ   ciency in the presence of 
inﬂ   ammation in critically ill patients. Th  is opens new 
areas of research exploring the role of iron treatment for 
these patients.
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